VRTX241220P445000
- 9.12
- -2.98-24.63%
Vertex Pharmaceuticals Newsroom
Vertex Pharmaceuticals Analyst Ratings
Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $494
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Raises Target Price to $494
Stifel Adjusts Price Target on Vertex Pharmaceuticals to $494 From $490, Maintains Hold Rating
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $525
Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
Vertex Pharmaceuticals Analyst Ratings
Jefferies Upgrades Vertex Pharmaceuticals to Buy From Hold, Adjusts Price Target to $550 From $500
Jefferies Upgrades Vertex Pharmaceuticals(VRTX.US) to Buy Rating, Raises Target Price to $550
Evercore ISI Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $506
RBC Capital Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $570 From $560
Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $486
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Vertex Pharmaceuticals (VRTX) Receives a Hold From Stifel Nicolaus
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $490
Vertex Pharmaceuticals Analyst Ratings
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $575